Innovent Expands Phase 3 IBI363 Lung Cancer Trial; Shares Fall

Innovent Biologics Inc. (1801.HK) said on Sept. 28, 2026, it expanded its global Phase 3 MarsLight-11 study of IBI363/TAK-928 to enroll patients with non-squamous non-small cell lung cancer. The Hong Kong-listed biopharmaceutical company's shares declined following the announcement. The trial expansion broadens the patient population for the immunotherapy candidate, which is being developed across oncology indications. Innovent did not disclose updated enrollment targets, timeline guidance, or financial terms in the release. The stock reaction reflects investor focus on clinical development risk and the costs of running a larger global late-stage program. Innovent develops therapies across oncology and other major disease areas.